Xencor (XNCR) AI Stock Analysis

• Market Cap: $552.75M
• Dividend Yield: N/A
• Average Volume (3M): 640.79K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.76
• Revenue Growth: -2.07%
• EPS Growth: 22.52%
• Country: US
• Employees: 250
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.41
• Shares Outstanding: 71,323,044
• 10 Day Avg. Volume: 843,308
• 30 Day Avg. Volume: 640,786
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: 2.15
• Enterprise Value/Gross Profit: 2.45
• Enterprise Value/Ebitda: -3.06
• 1Y Price Target: $24.28
• Price Target Upside: 214.51% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 43 Neutral
• Price Target: $7.50 ▼(-2.85% Downside)

Xencor's overall stock score is primarily impacted by its financial performance and technical analysis. The company's revenue growth is overshadowed by profitability challenges and weak cash flow. Technical indicators suggest bearish momentum, and the valuation is unattractive due to a negative P/E ratio. The recent board appointment is a positive but minor factor.

Positive Factors

Clinical Trials

Xencor recently initiated the Phase IIb XENITH-UC study with the TL1A antibody XmAb942 in ulcerative colitis following positive initial Phase I results.

Financial Performance

XNCR ended with $663.8M in cash and equivalents, with cash runway guidance extending into 2028.

Pipeline Development

Xencor's platforms have shown proof-of-concept of efficacy and safety across multiple assets and indications.

Negative Factors

Market Competition

Its potency and convenience is unmatched by current Phase II/III competitors, lending confidence in the recently initiated Phase IIb UC trial.

Regulatory Progress

Initial Phase I data with XmAb819 in renal cell carcinoma will be presented at a medical conference in the fourth quarter of 2025.

Xencor Business Overview & Revenue Model

Company Description

Xencor, Inc. is a biopharmaceutical company focused on the development of engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology platform to create novel therapeutics that enhance the efficacy and safety of antibody-based treatments. Xencor's pipeline includes multiple drug candidates that are in various stages of clinical development, targeting significant unmet medical needs in oncology and other therapeutic areas.

How the Company Makes Money

Xencor generates revenue primarily through collaborations and partnerships with larger pharmaceutical companies, which include upfront payments, research funding, and milestone payments tied to the progression of drug candidates through clinical trials. Additionally, the company may earn royalties on future sales of products that are commercialized through these partnerships. Xencor also engages in licensing its XmAb technology platform to other companies, further contributing to its revenue streams. The success of its drug candidates in clinical trials and eventual commercialization are critical factors influencing its earnings.

Xencor Financial Statement Overview

Summary

Xencor faces significant financial challenges with declining revenues and profitability. The income statement shows negative net profit and declining revenues, with a concerning revenue growth rate. The balance sheet shows a low debt-to-equity ratio and a strong equity reliance, but negative ROE is a concern. Cash flow issues are significant, with negative free cash flow growth, posing risks to financial stability.

Income Statement

Xencor's income statement reveals a challenging environment with negative net profit and declining revenues. The company recorded a negative net profit margin of -163.3% and a gross profit margin of 97.7% in the TTM, indicating high costs relative to revenue. The revenue growth rate is concerning, as revenues decreased from $275.1 million in 2021 to $130.4 million in the TTM. Despite a high gross profit margin, other profitability metrics such as EBIT and EBITDA margins are negative, suggesting operational inefficiencies.

Balance Sheet

The balance sheet shows a stable equity position with a debt-to-equity ratio of 0.11, indicating low leverage. The equity ratio stands at 70.7%, suggesting a strong reliance on equity over debt. However, the return on equity (ROE) is negative at -33.3% due to net losses, which is a concern for investors looking for returns on their equity.

Cash Flow

Xencor's cash flow statement shows negative free cash flow growth, with free cash flow at -$173 million in the TTM. The operating cash flow to net income ratio is also negative, reflecting challenges in converting income into cash. The company experienced a negative free cash flow to net income ratio, highlighting potential liquidity issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	164.15M	110.49M	168.34M	164.58M	275.11M	122.69M
Gross Profit	143.94M	110.49M	-85.26M	155.78M	267.62M	-47.11M
EBITDA	-115.24M	-186.17M	-125.87M	-72.16M	51.26M	-71.00M
Net Income	-177.87M	-232.62M	-126.09M	-55.18M	82.63M	-63.54M
Balance Sheet
Total Assets	879.42M	951.95M	952.69M	846.27M	838.21M	703.24M
Cash, Cash Equivalents and Short-Term Investments	443.86M	497.77M	593.73M	623.06M	334.11M	603.00M
Total Debt	67.93M	231.95M	83.43M	59.63M	33.97M	11.63M
Total Liabilities	259.07M	277.92M	283.56M	118.77M	104.71M	130.80M
Stockholders Equity	620.35M	677.61M	668.80M	727.50M	733.50M	572.44M
Cash Flow
Free Cash Flow	-140.81M	-208.28M	63.86M	-18.92M	-32.83M	-18.77M
Operating Cash Flow	-134.18M	-202.19M	85.11M	24.48M	-16.85M	-5.00M
Investing Cash Flow	-52.06M	-7.87M	-111.06M	-119.72M	-46.25M	100.19M
Financing Cash Flow	199.82M	197.15M	26.18M	5.70M	43.04M	18.04M

Xencor Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.72
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XNCR, the sentiment is Negative. The current price of 7.72 is below the 20-day moving average (MA) of 8.38, below the 50-day MA of 8.61, and below the 200-day MA of 14.66, indicating a bearish trend. The MACD of -0.36 indicates Positive momentum. The RSI at 42.16 is Neutral, neither overbought nor oversold. The STOCH value of 31.32 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for XNCR.

Xencor Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	76 Outperform	$738.70M	20.01	18.17%	―	1218.82%	―
Sector *	51 Neutral	$7.44B	-0.22	-45.45%	2.27%	23.06%	-2.29%
DNTH	48 Neutral	$640.55M	―	-34.71%	―	17.87%	41.27%
RLAY	45 Neutral	$577.58M	―	-46.24%	―	-76.27%	22.77%
XNCR	43 Neutral	$552.75M	―	-29.22%	―	-2.07%	22.52%
MRVI	42 Neutral	$685.03M	―	-55.41%	―	-22.52%	-37.00%
AUTL	41 Neutral	$573.53M	―	-52.18%	―	187.52%	26.32%

Xencor Corporate Events

Xencor Appoints Raymond Deshaies to Board of Directors

On July 31, 2025, Xencor announced the appointment of Raymond J. Deshaies, Ph.D., to its board of directors. Dr. Deshaies, a renowned biochemist and cell biologist with extensive experience in biotechnology and drug development, previously served as senior vice president of global research at Amgen Inc. His appointment is expected to bolster Xencor’s efforts in advancing its pipeline of XmAb drug candidates through clinical development, leveraging his deep understanding of biological mechanisms and track record of translating scientific insights into transformative medicines.

The most recent analyst rating on (XNCR) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.

Xencor Holds Annual Stockholders Meeting on June 12

On June 12, 2025, Xencor, Inc. held its Annual Meeting of Stockholders, where 94.68% of the company’s shares were represented. During the meeting, stockholders elected eight directors, ratified KPMG LLP as the independent accounting firm, approved an amendment to increase shares in the Equity Incentive Plan by 3,000,000, and supported the executive compensation plan.

The most recent analyst rating on (XNCR) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on Xencor stock, see the XNCR Stock Forecast page.